Design of a drug delivery system for targeting based on pharmacokinetic consideration

Advanced Drug Delivery Reviews

Volumn 19, Issue 3, 1996, Pages 335-357

  Suzuki, Hiroshi ^a   Nakai, Daisuke ^a   Seita, Takeshi ^a   Sugiyama, Yuichi ^a  

^a UNIVERSITY OF TOKYO   (Japan)

Author keywords

Anticancer drugs; Antisense DNA; Drug delivery system; Drug targeting; Intra arterial cancer chemotherapy; Pharmacodynamics; Pharmacokinetics; Receptor mediated targeting

Indexed keywords

CELLS; CHEMICAL MODIFICATION; DISSOCIATION; DNA; DRUG PRODUCTS; ENZYMES; MACROMOLECULES; MATHEMATICAL MODELS; MICELLES; PHARMACODYNAMICS; PHARMACOKINETICS; POLYMERS;

ANTICANCER DRUGS; DRUG TARGETING SYSTEM; INTRA-ARTERIAL CANCER CHEMOTHERAPY; RECEPTOR MEDIATED ENDOCYTOSIS;

CONTROLLED DRUG DELIVERY;

ANTINEOPLASTIC AGENT; BOVINE SERUM ALBUMIN; CARMUSTINE; CISPLATIN; COMPLEMENTARY DNA; CYTARABINE; DOXORUBICIN; DRUG CARRIER; FLUOROURACIL; MACROGOL; MEMBRANE RECEPTOR; POLYASPARTIC ACID; POLYLYSINE; POLYMER;

AREA UNDER THE CURVE; DISSOCIATION CONSTANT; DRUG DELIVERY SYSTEM; DRUG MECHANISM; DRUG METABOLISM; DRUG TARGETING; ENDOCYTOSIS; ENZYME MODIFICATION; EXPOSURE; HUMAN; INTRAARTERIAL DRUG ADMINISTRATION; INTRAVENOUS DRUG ADMINISTRATION; MACROMOLECULE; MICELLE; MICHAELIS CONSTANT; MODEL; NONHUMAN; PHARMACEUTICS; PHARMACODYNAMICS; PHARMACOKINETICS; PRIORITY JOURNAL; REVIEW; TARGET ORGAN;

EID: 0030580943     PISSN: 0169409X     EISSN: None     Source Type: Journal    
DOI: 10.1016/0169-409X(96)00008-7     Document Type: Review

References (84)

1. [1] Lee, V.H., Hashida, M. and Mizushima, Y. (1995) Trends and Future Perspectives in Peptide and Protein Drug Delivery, Harwood Academic Publishers, Chur, Switzerland.
2. [2] Chien, Y.W. (1992) Novel drug delivery systems, Marcel Dekker, New York, NY.
3. [3] Yokoyama, M. (1992) Block copolymers as drug carriers. Crit. Rev. Ther. Drug Carrier Syst. 9, 213-248.
4. [4] Gregoriadis, G. (1988) Liposomes as drug carriers, Wiley, New York, NY.
5. [5] Senior, J.H. (1987) Fate and behavior of liposomes in vivo: A review of controlling factors. Crit. Rev. Ther. Drug Carrier Syst. 3, 123-193.
6. [6] Pardridge, W.M. (1991) Antibody delivery through the blood-brain barrier. In: Pardridge, W.M. (Ed), Peptide Drug Delivery to the Brain, Raven Press, New York, NY, pp. 219-238.
7. [7] Huennekens, F.M. (1994) Tumor targeting: Activation of prodrugs by enzyme-monoclonal antibody conjugates. Trends Biotechnol. 12, 234-239.
8. [8] Perales, J.C., Ferkol, T., Molas, M. and Hanson, R.W. (1994) An evaluation of receptor-mediated gene transfer using synthetic DNA-ligand complexes. Eur. J. Biochem. 226, 255-266.
9. [9] Molema, G. and Meijer, D.K.F. (1994) Targeting of drugs to various blood cell types using (neo-)glycoproteins, antibodies and other protein carriers. Adv. Drug Deliv. Rev. 14, 25-50.
10. [10] Meijer, D.K.F. and Molema, G. (1995) Targeting of drugs to the liver. Semin. Liver Dis. 15, 202-255.
11. [11] Sugiyama, Y. and Kato, Y. (1994) Pharmacokinetic aspects of peptide delivery and targeting: Importance of receptor-mediated endocytosis. In: Chien, Y.W. and Hu, O.Y.-P. (Eds), Recent Developments in Transdermal and Advanced Drug Delivery, Marcel Dekker, New York, NY, pp. 591-614.
12. [12] Sugiyama, Y. and Hanano, M. (1989) Receptor-mediated transport of peptide hormones and its importance in the overall hormone disposition in the body. Pharm. Res. 6, 192-202.
13. [13] Sugiyama, Y. and Kato, Y. (1995) In vitro models of hepatic uptake: Methods to determine kinetic parameters for receptor-mediated hepatic uptake. In: Taylor, M.D. and Amidon, G.L. (Eds), Peptide-based Drug Design: Controlling Transport and Metabolism. ACS Professional Reference Book, American Chemical Society, Washington, DC, pp. 525-551.
14. [14] Wilkinson, G.R. (1987) Clearance approaches in pharmacology. Pharmacol. Rev. 39, 1-47.
15. [15] Gibaldi, M. and Perrier, D. (1982) Pharmacokinetics, Marcel Dekker, New York, NY.
16. [16] Rowland, M. and Tozer, T.N. (1980) Clinical Pharmacokinetics: Concepts and application, Lea and Febiger, New York, NY.
17. [17] Hunt, C.A., MacGregor, R.D. and Siegel, R.A. (1986) Engineering targeted in vivo drug delivery. I. The physiological and physicochemical principles governing opportunities and limitations. Pharm. Res. 3, 333-344.
18. [18] Siegel, R.A., MacGregor, R.D. and Hunt, C.A. (1991) Comparison and critique of two models for regional drug delivery. J. Pharmacokinet. Biopharmacol. 19, 363-374.
19. [19] Boddy, A.V. and Aarons, L.J. (1991) Application of a linear recirculation model to drug targeting. J. Pharmacokinet. Biopharmacol. 19, 355-362.
20. [20] Boddy, A.V. and Aarons, L.J. (1989) Pharmacokinetic and pharmacodynamic aspects of site-specific drug delivery. Adv. Drug Deliv. Rev. 3, 155-163.
21. [21] Boddy, A. Aarons, L. and Petrak, K. (1989) Efficiency of drug targeting: Steady-state considerations using a three-compartment model. Pharm. Res. 6, 367-372.
22. [22] Gupta, P.K. and Hung, C.T. (1989) Quantitative evaluation of targeted drug delivery systems. Int. J. Pharm. 56, 217-226.
23. [23] Levy, G. (1987) Targeted drug delivery: Some pharmacokinetic considerations. Pharm. Res. 4, 3-4.
24. [24] Eriksson, U.G. and Tozer, T.N. (1987) Pharmacokinetic evaluation of regional drug delivery. Acta Pharm. Jugosl. 37, 331-344.
25. [25] Jusko, W.J. (1971) Pharmacodynamics of chemotherapeutic effects: dose-time-response relationship for phase-nonspecific agents. J. Pharm. Sci. 60, 892-895.
26. [26] Jusko, W.J. (1973) A pharmacodynamic model for cell-cycle-phase-specific chemotherapeutic agents. J. Pharmacokinet. Biopharm. 1, 175-200.
27. [27] Shimoyama, M. (1975) Cytocidal action of anticancer agents: evaluation of the sensitivity of cultured animal and human cancer cells: In: Comparative Leukemic Research 1973, Leukemogenesis. University of Tokyo Press, Tokyo/Karger, Basel, pp. 711-722.
28. [28] Shimoyama, M. and Kimura, K. (1972) Quantitative clonal growth of mammalian cells: its application for quantitative study of cytocidal action of mitomycin C. Gann 63, 773-783.
29. [29] Ozawa, S., Sugiyama, Y., Mitsuhashi, Y., Kobayashi, T. and Inaba, M (1988) Cell killing action of cell cycle phase-non-specific antitumor agents is dependent on concentration-time product. Cancer Chemother. Pharmacol. 21, 185-190.
30. [30] Ozawa, S., Sugiyama, Y., Mitsuhashi, Y. and Inaba, M (1989) Kinetic analysis of cell killing effect induced by cytosine arabinoside and cisplatin in relation to cell cycle phase specificity in human colon cancer and Chinese hamster cells. Cancer Res. 49, 3823-3828.
31. [31] Mitsuhashi, Y., Inaba, M., Sugiyama, Y. and Kobayashi, T. (1992) In vitro measurement of chemosensitivity of human small cell lung and gastric cancer cell lines toward cell cycle phase-nonspecific agents under the clinically equivalent area under the curve. Cancer 70, 2540-2546.
32. [32] Fuse, E., Kobayashi, T., Inaba, M., Suzuki, H. and Sugiyama, Y. (1994) Application of pharmacokinetically guided dose escalation with respect to cell cycle phase specificity. J. Natl. Cancer Inst. 86, 989-996.
33. [33] Nakai, D., Fuse, E., Suzuki, H., Inaba, M. and Sugiyama, Y. (1996) Evaluation of the efficiency of targeting of antitumor drugs: Simulation analysis based on pharmacokinetic/pharmacodynamic considerations. J. Drug Target., in press.
34. [34] Ensminger, W.D., Rosowsky, A., Raso, B., Levin, D.C., Glode, M. Come, S., Steele, G. and Frei, E (1978) A clinical-pharmacological evaluation of hepatic arterial infusions of 5-fluoro-2′-deoxyuridine and 5-fluorouracil. Cancer Res. 38, 3784-3792.
35. [35] Collins, J.M. (1984) Pharmacokinetic rationale for intraarterial therapy. In: Howell, S.B. (Ed), Intra-arterial and Intracavitary Cancer Chemotherapy, Martinus Nijhoff, Boston, MA, pp. 1-10.
36. [36] Øie, S. and Huang, J.-D. (1981) Influence of administration route on drug delivery to a target organ. J. Pharm. Sci. 70, 1344-1347.
37. [37] Crooke, S.T. (1992) Therapeutic applications of oligonucleotides. Bio/Technology 10, 882-886.
38. [38] Wickstrom, E (1992) Strategies for administering targeted therapeutic oligodeoxynucleotides. Trends Biotechnol. 10, 281-287.
39. [39] Stein, C.A. and Cheng, Y.-C. (1993) Antisense oligonucleotides as therapeutic agents - Is the bullet really magical? Science 261, 1004-1012.
40. [40] Hargrove, J.L. (1993) Microcomputer assisted kinetic modeling of mammalian gene expression. FASEB J. 7, 1163-1170.
41. [41] Stella, V.J. (1980) Prodrugs and site-specific drug delivery. J. Med. Chem. 23, 1275-1282.
42. [42] Rowland, M. (1988) Bioavailability assessment and pharmacologic response: Impact of first-pass loss when both drug and metabolites are active. J. Pharmacokinet. Biopharm. 16, 573-593.
43. [43] Audus K.L. and Borchardt, R.T. (1987) Bovine brain microvessel endothelial cell monolayers as a model system for the blood-brain barrier. Ann. N.Y. Acad. Sci. 507, 9-18.
44. [44] Takakura, Y., Mahato, R.I., Nishikawa, M. and Hashida, M. (1996) Control of pharmacokinetic profiles of drug-macromolecule conjugates. Adv. Drug Deliv. Rev., in press.
45. [45] Takakura, Y. and Hashida, M. (1995) Macromolecular drug carrier systems in cancer chemotherapy: Macromolecular prodrugs. Crit. Rev. Oncol. Hematol. 18, 207-231.
46. [46] Takakura, Y., Takagi, A., Hashida, M. and Sezaki, H. (1987) Disposition and tumor localization of mitomycin C-dextran conjugates in mice. Pharm. Res. 4, 293-300.
47. [47] Pyatak, P.S., Abuchowski, A. and Davis, F.F. (1980) Preparation of a polyethylene glycol: Superoxide dismutase adduct, and an examination of its blood circulation life and anti-inflammatory activity, Res. Commun. Chem. Pathol. Pharmacol. 29, 113-127.
48. [48] Liu, T.H., Beckman, J.S., Freeman, B.A., Hogan, E.L. and Hsu, C.Y. (1989) Polyethylene glycol-conjugated superoxide dismutase and catalase reduced ischemic brain injury, Am. J. Physiol. 256, H589-H593.
49. [49] Miyata, K., Nakagawa, Y., Nakamura, M., Ito, T., Sugo, K., Fugita, J. and Tomoda, K. (1988) Altered properties of serratia superoxide dismutase by chemical modification, Agric. Biol. Chem. 52, 1575-1581.
50. [50] Kimura, H., Matusmura, Y, Miyauchi, Y. and Maeda, H. (1988) A new tactic for the treatment of jaundice: An injectable polymer-conjugated bilirubin oxidase. Proc. Soc. Exp. Biol. Med. 188, 364-369.
51. [51] Sugi, K., Inoue, M., Morino, Y. (1989) Degradation of plasma bilirubin by a bilirubin oxidase derivative which has a relatively long half-life in the circulation. Biochim. Biophys. Acta 991, 405-409.
52. [52] Ogino, T., Inoue, M., Ando, Y., Awai, M., Maeda, H., Morino, Y. (1988) Chemical modification of superoxide dismutase: Extension of plasma half life of the enzyme through its reversible binding to the circulating albumin. Int. J. Pept. Protein Res. 32, 153-159.
53. [53] Inoue, M. Watanabe, N., Morino, Y., Tanaka, Y., Amachi, T. and Sasaki, J. (1990) Inhibition of oxygen toxicity by targeting superoxide dismutase to endothelial cell surface. FEBS Lett. 269, 89-92.
54. [54] Inoue, M., Watanabe, N., Matsuno, K., Sasaki, J., Tanaka, Y., Hatanaka, H. and Amachi, T. (1991) Expression of a hybrid Cu/Zu-type superoxide dismutase which has high affinity for heparin-like proteoglycans on vascular endothelial cells. J. Biol. Chem. 266, 16409-16414.
55. [55] Nakazono, K., Watanabe, N., Matsuno, K., Sasaki, J. Sato, T. and Inoue, M. (1991) Does superoxide underlie the pathogenesis of hypertension? Proc. Natl. Acad. Sci. USA 88, 10045-10048.
56. [56] Liu, K.-X., Kato, Y., Narukawa, M., Kim, D.C., Hanano, M., Higuchi, O., Nakamura, T. and Sugiyama, Y. (1992) Importance of the liver in plasma clearance of hepatocyte growth factor in rats. Am. J. Physiol. 263, G642-G649.
57. [57] Liu, K.-X., Kato, Y. Yamazaki, M., Higuchi, O., Nakamura, T. and Sugiyama, Y. (1993) Decrease in the hepatic clearance of hepatocyte growth factor in carbon tetrachloride-intoxicated rats. Hepatology 17, 651-660.
58. [58] Kato, Y., Liu, K.-X., Nakamura, T. and Sugiyama, Y. (1994) Heparin-hepatocyte growth factor complex with low plasma clearance and retained hepatocyte proliferating activity. Hepatology 20, 417-424.
59. [59] Yokoyama, M., Kwon, G.S., Okano, T., Sakurai, Y., Seto, T. and Kataoka, K. (1992) Preparation of micelle-forming polymer-drug conjugate. Bioconj. Chem. 3, 295-301.
60. [60] Yokoyama, M., Kwon, G.S., Okano, T., Sakurai, Y., Ekimoto, H., Okamoto, K., Mashiba, H., Seto, T. and Kataoka, K. (1992) Composition-dependent in vivo antitumor activity of adriamycin-conjugated polymeric micelle against murine colon adenocarcinoma 26. Drug Deliv. 1, 11-19
61. [61] Yokoyama, M., Okano, T., Sakurai, Y., Ekimoto, H., Shibazaki, C. and Kataoka, K. (1991) Toxicity and antitumor activity against solid tumors of micelle-forming polymeric anticancer drug and its extremely long circulation in blood. Cancer Res. 51, 3229-3236.
62. [62] Yokoyama, M., Miyauchi, M., Yamada, N., Okano, T., Sakurai, Y., Kataoka, K. and Inoue, S. (1990) Characterization and anticancer activity of the micelle-forming polymeric anticancer drug adriamycin-conjugated poly-(ethylene glycol)-poly(aspartic acid) block copolymer. Cancer Res. 50, 1693-1700.
63. [63] Yokoyama, M., Inoue, S., Kataoka, K., Yui, N., Okano, T. and Sakurai, Y. (1989) Molecular design for missile drug: Synthesis of adriamycin conjugated with immunoglobulin G using poty(ethylene glycol-block-poly(aspartic acid) as intermediate carrier. Macromol. Chem. 190, 2041-2054.
64. [64] Maeda, H., Takeshita, J. and Kanamura, R. (1979) A lipophilic derivatives of neocarzinostatin. A polymer conjugation of an antitumor protein antibiotic. Int. J. Pept. Protein Res. 14, 81-87.
65. [65] Maeda, H., Ueda, M., Morinaga, T. and Matsumoto, T. (1985) Conjugation of poly (styrene-co-maleic acid) derivatives to the antitumor protein neocarzinostatin: Pronounced improvements in pharmacological properties. J. Med. Chem. 28, 455-461.
66. [66] Kobayashi, A., Oda, T. and Maeda, H. (1988) Protein binding of macromolecular anticancer agent SMANCS: Characterization of poly (styrene-co-maleic acid) derivatives as albumin binding ligand. J. Bioact. Compat. Polym. 3, 319-333.
67. [67] Maeda, H. and Matsunuma, Y. (1989) Tumortropic and lymphotropic principles of macromolecular drugs. Crit. Rev. Ther. Drug Carrier Syst. 6, 193-210.
68. [68] Matsunuma, Y. and Maeda, H. (1986) A new concept for macromolecular therapeutics in cancer chemotherapy: Mechanism of tumortropic accumulation of proteins and the anticancer agent SMANCS. Cancer Res. 46, 6387-6392.
69. [69] Maeda, H., Matsumoto, K., Konno, T., Iwai, K. and Ueda, M. (1984) Tailor-making of protein drugs by polymer conjugation for tumor targeting. J. Protein Chem. 3, 181-193.
70. [70] Peterson, H.I. and Appelgren, K.L. (1973) Experimental studies on the uptake and retention of labelled proteins in a rat tumor. Eur. J. Cancer Clin. Oncol. 9, 543-547.
71. [71] Breitfeld, P.P., Simmons Jr., C.F., Strous, G.J.A.M., Gueze, H.J. and Schwartz, A.L. (1985) Cell biology of the asialoglycoprotein receptor system: A model for receptor-mediated endocytosis. Int. Rev. Cytol. 97, 47-95.
72. [72] Wilson, F. (1978) Effect of reductive lactosamination on the hepatic uptake of bovine pancreatic ribonuclease A dimer. J. Biol. Chem. 266, 18162-18171.
73. [73] Wu, G.Y. and Wu, C.H. (1992) Specific inhibition of hepatitis B viral gene expression in vitro by targeted antisense oligonucleotides. J. Biol. Chem. 267, 12436-12439.
74. [74] Seita, T, Nakai, D. Terasaki, T. and Sugiyama, Y. (1994) Delivery of antisense DNA to the liver by utilizing the asialoglycoprotein receptor: Experimental and theoretical approaches. In: Progress in Drug Delivery Systems III, Biomedical Research Foundation, Tokyo, pp. 29-42.
75. [75] Seita, T., Nakai, D. and Sugiyama, Y. (1995) Pharmacokinetics and drug delivery system of antisense DNA. Pharm. Tech. Jpn. 11, 27-39 and 151-163.
76. [76] Inaba, M., Mitsuhashi, J. and Ozawa, S. (1990) Kinetic analysis of 5-fluorouracil action against various cancer cells. Jpn. J. Cancer Res. 81, 1039-1044.
77. [77] Collins, J.M., Grieshaber, C.K. and Chabner, B.A. (1990) Pharmacologically guided phase I clinical trials based upon preclinical drug development. J. Natl. Cancer Inst. 82, 1321-1326.
78. [78] Fuse, E., Kobayashi, T., Inaba, M. and Sugiyama, Y. (1995) Prediction of the maximal tolerated dose (MTD) and therapeutic effect of anticancer drugs in humans: integration of pharmacokinetics with pharmacodynamics and toxicodynamics. Cancer Treatment Rev. 21, 133-157.
79. [79] Milano, G., Roman, P., Khater, R., Frenay, M, Renee, N. and Namer, M. (1988) Dose versus pharmacokinetics for predicting tolerance to 5-day continuous infusion of 5-FU. Int. J. Cancer 41, 537-541.
80. [80] Goldberg, J.A., Kerr, D.J., Watson, D.G., Willmott, N., Bates, C.D., McKillop, J.H. and McArdle, C.S. (1990) The pharmacokinetics of 5-fluorouracil administered by arterial infusion in advanced colorectal hepatic metastases. Br. J. Cancer 61, 913-915.
81. [81] Boublil, J.-L., Milano, G., Khater, R., Bourry, J., Thyss, A., Bruneton, J.-N., Renee, N., Philip, C. and Namer, M. (1985) Br. J. Cancer, 52, 15-20.
82. [82] Collins, J.M., Dedrick, R.L., Frankliin, G., King, D., Speyer, J.L. and Myers, C.E. (1980) Nonlinear pharmacokinetic models for 5-fluorouracil in man: Intravenous and intraperitoneal routes. Clin. Pharm. Ther. 28, 235-246.
83. [83] Arai, Y., Kido, C. and Ariyoshi, Y. (1993) Pharmacokinetics in arterial infusion chemotherapy. Jpn. J. Cancer Chemother. 20, 1755-1761.
84. [84] Nakai, D., Seita, T. and Sugiyama, Y. (1994) Pharmacokinetics and drug delivery system of antisense DNA. Pharm. Tech. Jpn. 10, 1103-1118, 1403-1415 and 1537-1551.